The purpose of immunosuppression is to prevent the recipient's immune system from destroying or damaging the graft. Immunosuppression aims to balance under-immunosuppression leading to graft rejection and over-immunosuppression leading to sepsis and malignancy. There have been comparatively few studies on which to base a rational approach to immunosuppression. The types of immunosuppressants are 1) purine analogues such as 6-mercaptopurine (6-MP), 2) inhibitors of inosine monophosphate dehydrogenase such as myciphenolate mofetil (MMF), 3) glucocorticoids such as prednisone, 4) calcineurin binding drugs such as cyclosporin and tacrolimus, 5) TOR inhibitors such as sirolimus, and 6) mono-and polyclonal antibodies. There are five phases in the management of immunosuppression: 1) induction, 2) maintenance, 3) treatment of acute rejection, 4) treatment of chronic rejection, and 5) withdrawal of immunosuppression. Immunosuppression is complicated by intercurrent infection, usually viral or tubucular, and by pregnancy, breast feeding, diabetes mellitus, and renal impairment. The purpose of immunosuppression is to prevent the body's immune system destroying or damaging the graft. Since currently available drugs are not specific for graft alloantigens, the clinician must maintain a balance between under-immunosuppression, leading to graft rejection, and overimmunosuppression, leading to the consequences of immunodeficiency such as sepsis and malignancy. The clinician should also be aware of, and attempt to minimize, the unwanted effects of long-term use of these agents.
The purpose of immunosuppression is to prevent the body's immune system destroying or damaging the graft. Since currently available drugs are not specific for graft alloantigens, the clinician must maintain a balance between under-immunosuppression, leading to graft rejection, and overimmunosuppression, leading to the consequences of immunodeficiency such as sepsis and malignancy. The clinician should also be aware of, and attempt to minimize, the unwanted effects of long-term use of these agents.
In the early days of liver transplantation, the protocols for liver allograft recipients were derived by extrapolation from renal transplantation. It has become clear, however, that different approaches need to be adopted: for example, in liver allograft recipients, tolerance may develop and those strategies that aim to abolish early acute rejection may inhibit the development of tolerance. While acute rejection is associated with a poor outcome in renal transplantation, there is no evidence that acute cellular rejection, which is reversed by short periods of increased immunosuppression (so-called reversible acute cellular rejection), has any untoward effect on liver graft survival.
There have been comparatively few studies on which to base a rational approach to immunosuppression: the success of liver transplantation has meant that to demonstrate significant improvement in graft survival or a reduction in the immunosuppressive-related morbidity, a large number of patients need to be followed for long periods of time. In the present climate, this is usually difficult. Furthermore, the introduction of newer agents, or improved formulations of existing drugs, means that the conclusions of randomized trials may be superseded before results are available.
Most centers have adopted a common approach to the principles of immunosuppression but differ significantly in the details. Therefore, in this article, the principles of immunosuppression will be outlined together with a description of the conse- quences of over-immunosuppression. Details of those drugs that are currently available and those shortly to be licensed will be described.
Drugs and Other Agents Used in Immunosuppression
The drugs and other agents and procedures used for immunosuppression are shown in Table 1, and  details of those drugs and agents licensed for immunosuppression are shown in Tables 2 to 13 .
Types of Immunosuppression
Immunosuppression may be physical or pharmacological. Physical methods, as shown in Table 1 , are rarely used in liver transplantation.
Medications Used for Immunosuppression

Purine Analogues
Azathioprine has been used for many years in transplantation (see Table 3 ). It is metabolized by thiopurine methyltransferase to the active component 6-mercaptopurine (6-MP), an analogue of the natural purines hypoxanthine and adenine. 6-MP is then metabolized to thioinosine monophosphate, which inhibits synthesis of DNA precursor molecules and interferes with nucleic acid synthesis during clonal expansion of lymphocytes. People who have low levels of thiopurine methyltransferase are more susceptible to the side effects of azathioprine but may tolerate 6-MP.
The rationale for long-term use of azathioprine is not well established, although several studies have suggested an increased probability of chronic rejection in patients not taking azathioprine. Following the introduction of azathioprine (usually at a dose of 1-2 mg/kg/day), the white count should be monitored twice monthly for 3 months: if the white count falls below 4.0 × 10.9/l, the dose should be halved; if the white count falls below 3.0 × 10.9/l, azathioprine should be discontinued.
Veno-occlusive disease and hepatitis are the most serious forms of liver dysfunction associated with azathioprine and usually develop within the first 6 months. (Table 4) Mycophenolate mofetil acts by inhibition of inosine monophosphate dehydrogenase; it is colloquially referred to as MMF.
IMPDH Inhibitors
Glucocorticoids
These agents have both anti-inflammatory and immunosuppressive effects. The glucocorticoids bind to the glucocorticoid receptor, and the complex then translocates to the nucleus where, after binding to DNA, protein synthesis is affected. Among the intranuclear functions altered by glucocorticoids is synthesis of nuclear factor kappa B (NF-κB), resulting in apoptosis of lymphocytes. There are many different glucocorticoids used in transplantation, and the potency on a weight-forweight basis varies and is summarized in Table 5 .
There is increasing evidence that corticosteroids can be withdrawn by 3 months or earlier in most liver transplant recipients. In contrast, some centers maintain corticosteroids in patients grafted for autoimmune hepatitis to prevent recurrent disease in the allograft (see Table 6 ). (Tables 7 and 8 ) Both cyclosporin and tacrolimus bind to immunophilins, which are widely distributed intracellular proline isomerases. Cyclosporin binds to cyclophilin and tacrolimus to the FK-binding protein, which results in inhibition of calcineurin, which inhibits activation of transcription factors such as NFATc, a transcriptional factor responsible for the calcium activation of cytokine genes during the immune response. Other downstream effects are thought to relate to some of the side effects of this class of drugs including diabetes and renal impairment. Tacrolimus is well absorbed from the upper GI tract. Consequently, there is rarely an indication to give tacrolimus intravenously. The starting dose is 0.1 mg/kg/day in two divided doses: target levels for the first 3 months lie between 10 and 15 ng/ml (trough whole blood levels measured by RIA) and between 5 and 10 ng/ml thereafter.
Cyclosporin is fat soluble, and absorption is variable from the gut, especially in the early postoperative period when bile production and flow may be compromised. The microemulsion form is absorbed in a more consistent fashion, and there is rarely a need to administer cyclosporin intravenously. The starting dose is 8 mg/kg/day and the dose adjusted to trough whole blood levels between 150 and 200 ng/ml for the first 3 months and 100-150 ng/ml thereafter. However, measurement of blood levels taken 2 hours postdose (otherwise called C-2) may provide a better assessment of drug monitoring.
Tacrolimus and cyclosporin are metabolized by oxidation through the cytochrome P450 system. The liver is the main site of metabolism, although minor metabolism occurs in the gut. Drugs that induce or inhibit cytochromes P450, such as erythro- mycin, ketoconazole, or rifampicin, interact with tacrolimus and cyclosporin and may affect drug levels. Drug interactions are listed in Table 9 . Calcineurin inhibitors (cyclosporin and tacrolimus) are the current mainstays of maintenance immunosuppression. Both agents are associated with significant side effects in the long term. There are several studies comparing the two drugs, and these suggest that tacrolimus may be superior. For both drugs, target levels have been derived from clinical experience, although the dose should be adjusted in the light of complications (such as renal impairment or symptoms such as headaches or tremors) and liver function. (Table 10) Sirolimus (previously known as rapamycin) inhibits lymphocyte proliferation mediated by cytokines such as IL-2 and IL-4. Sirolimus, like tacrolimus, binds to the immunophilin called FK binding protein (FKBP), but it does not inhibit the calcineurin pathway. The sirolimus-immunophilin complex interacts with a protein kinase called TOR ("target of rapamycin") that is integral to a signal transduction pathway regulating the synthesis of proteins required for cell-cycle progression in both lymphoid and nonlymphoid cells.
TOR Inhibitors
Sirolimus is poorly absorbed from the gut. It is widely distributed in many tissues. The liver is the principal organ of metabolism, via the cytochrome P450 3A4 system. The half-life is approximately 50-70 hours in healthy subjects and renal transplant recipients and is considerably lengthened in patients with chronic liver dysfunction. The most frequently reported adverse effects in subjects receiving sirolimus are mild dose-related thrombocy- Immunosuppressive Antibodies (Tables 11-13 ) Antibodies may be mono-or polyclonal. Some preparations react with epitopes expressed by all lymphocytes, whereas others recognize epitopes expressed by subsets of lymphocytes only. All are profoundly immunosuppressive. Some centers use polyclonal antibodies to lymphocytes (e.g., ALG, Thymoglobulin) for induction (see Table 9 ).
Principles of Immunosuppression
The management of immunosuppression can be considered in five phases:
Induction of Immunosuppression
There is no consensus for the optimal method for induction of immunosuppression. Some centers use mono-or polyclonal antibodies, in combination with other immunosuppressive agents. Other centers use intraoperative corticosteroids. There are two preparations: Basiliximab is a chimeric monoclonal antibody and is given at a dose of 20 mg within 2 hours of surgery and at 4 days (children below 15 years have a smaller dose). Daclizumab is a humanized monoclonal antibody: the dose is 1 mg/kg/dose for 5 doses, the first within 24 hours of transplantation. The initial dose required for liver transplants may be greater than for other solid organ recipients due to loss of antibody in ascites drained at laparotomy, and in ascitic or pleural fluid drained during the perioperative period 
Maintenance of Immunosuppression
Currently most centers use a combination of corticosteroids, azathioprine, and a calcineurin inhibitor, although some use monotherapy (calcineurin inhibitor alone) or dual therapy (calcineurin inhibitor with azathioprine or mycophenolate), but there are few data to define the optimal regime. The introduction into clinical practice of newer drugs such as sirolimus will allow the clinician to tailor the immunosuppressive regime more closely to the patient.
Treatment of Acute Rejection
Acute rejection should, whenever possible, be confirmed prior to treatment using histology obtained by liver biopsy; fine needle aspiration biopsy is used occasionally. Although many serological markers in blood and bile have been described, none has been shown to be of adequate sensitivity and specificity to confirm rejection. It is rarely possible to distinguish reliably between rejection and infection without histology.
The mainstay of immunosuppression for early acute rejection is high-dose corticosteroids: regimes vary between centers, and there are no good data to demonstrate superiority of any one regime. Typical regimes are
• Prednisolone 200 mg/day for 3 days • Methyl prednisolone 0.5-1 g/day for 3 days
The rate of reduction of corticosteroid pulses to maintenance steroids varies from center to center.
Treatment of Chronic Rejection
Chronic rejection of the liver allograft has many names: chronic ductopenic rejection, vanishing bile duct syndrome, chronic rejection. Chronic ductopenic rejection may lead to loss of the graft. It is treated by increased immunosuppression, including conversion to tacrolimus from cyclosporin or switching to sirolimus.
Withdrawal of Immunosuppression
The observation that some patients have maintained long-term good graft function after discontinuing immunosuppression has led some centers to embark on carefully controlled trials of withdrawal of all immunosuppression in long-term (>5 years) survivors with good graft function, or in subjects with major impediments to continued use of immunosuppressants, such as malignant disease. These studies have demonstrated that it is possible to withdraw all immunosuppression in about 20% of carefully selected patients. The remainder required maintenance immunosuppressants or their reintroduction if they had been stopped. The usual reason for failure to withdraw immunosuppressants was late onset acute cellular rejection, which was then controlled by adjusted phamacotherapy. Those recipients grafted for non-autoimmune diseases, without episodes of acute rejection and with a good HLA match, are more likely to be able to withdraw immunosuppression.
Side Effects of Immunosuppression
The side effects of immunosuppression may be due either to
• The effect of immunosuppression itself (especially infection and malignancy) • The effects of individual drugs
Tailoring the Immunosuppression to the Individual
Since different drugs have differing effects and side effects both on the patient and the disease, it is important not to adopt one regime for all patients but to tailor the drug regime for the individual. The probability of developing acute rejection is, in part, dependent on the indication for transplantation so that patients grafted for viral hepatitis (especially B) and alcohol-associated liver disease have a much lower probability of developing early rejection than those grafted for autoimmune diseases such as PBC or AIH.
Intercurrent Bacterial Infections
Currently available immunosuppressants will not only reduce the risk of rejection but also predispose the patient to infection. The balance between overand under-immunosuppression is even more difficult to maintain in the presence of active sepsis. The general approach is to reduce the immunosuppression but the onset of graft rejection may not only herald the need for high-dose immunosuppression but hepatic impairment is associated with a further reduction in the host defenses against infection. In the presence of bacterial infection, early detection and vigorous treatment with appropriate antimicrobials is clearly required; depending on liver function, steroids should be reduced initially. Remember, however, in maintaining the balance between rejection and infection, with rejection the graft will be lost, but with infection the patient will be lost.
Intercurrent Viral Infection
The most common viral infection during the early postoperative period is cytomegalovirus (CMV). CMV is associated with chronic rejection: this may be related to a direct effect of CMV on the biliary epithelial cells and, in part, to the reduction in immunosuppression. It is important, therefore, to reduce the immunosuppressive therapy in association with active antiviral treatment. A common practice is to stop azathioprine and reduce the calcineurin inhibitor.
Tuberculosis
Because of the severe course of reactivation of tuberculosis in the patient on immunosuppression, most centers use prophylactic treatment with isoniazid 100 mg/day in those at risk. Isoniazid should be given with pyridoxine. Treatment should be for at least 1 year.
Retransplantation for Chronic Rejection, Late Acute Rejection, and Early Ductopenic Rejection
These are associated with an increased risk of developing graft loss, and therefore many centers are 
